This post was originally published on this site Medicare will provide nationwide coverage for CAR T-cell therapies, an innovative anti-cancer treatment, for certain types of lymphoma and leukemia, the Centers for Medicare & Medicaid Services (CMS) has announced. Medicare will pay for this costly therapy to all cancer patients falling under the labels approved by…
Category: <span>Cancer</span>
Trial Testing Potential Cancer Therapy THOR-707 Starts Dosing in Australia, Cleared to Enroll in U.S.
This post was originally published on this site A Phase 1/2 trial testing the advanced tumors treatment candidate THOR-707 has begun dosing patients in Australia — and has been cleared by the U.S. Food and Drug Administration to enroll participants in the U.S. Australia is the first country recruiting patients for the global HAMMER trial…
‘Chemopause’: Too Hot to Trot
This post was originally published on this site My boss brought it up a couple of times, but the rule was clear: Polite people don’t mention it. Norma didn’t follow that rule. She’d walk down the hall fanning herself, her sweater flung over the nearest chair and her skin suddenly flushed red. “I’m having a…
Breast, Ovarian Cancer Therapy Seen to Delay to Progression in Advanced Prostate Cancers in Phase 3 Trial
This post was originally published on this site Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time without disease progression or death compared to those given standard treatment with Xtandi (enzalutamide) or Zytiga (abiraterone) in a Phase 3 trial. The multicenter, open-label PROfound study…
Optimal Just-in-Time Approach Accelerates Enrollment in Trials
This post was originally published on this site Using an approach called Optimal Just-in-Time (JIT) has shortened the start of patient enrollment in clinical trials of both solid tumors and blood cancers from eight months to only two weeks. Among other advantages, the methodology also enabled the recruitment of more diverse patient populations than traditional…
‘Moving Mountains for Multiple Myeloma’ Takes Trek Challenge to Iceland
This post was originally published on this site Aiming to both inspire the multiple myeloma community and raise money to accelerate treatments, members of Moving Mountains for Multiple Myeloma (MM4MM) recently traversed Iceland’s impressive landscape. The 14-member excursion included two patients plus caregivers, family members, myeloma specialists, and individuals from organizing partners. The MM4MM initiative is a…
Fujifilm’s New Imaging Option Can Enhance Accuracy of Breast Biopsy
This post was originally published on this site Fujifilm Medical Systems USA has expanded its breast cancer imaging toolbox by releasing a new tomosynthesis option for its ASPIRE Cristalle mammography technology, which improves accuracy of breast biopsy. The new Tomosynthesis Biopsy solution determines the three-dimensional coordinates of a suspicious lesion in the breast. According to…
AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest
This post was originally published on this site Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking part in a Phase 1b/2 trial show. The company will increase enrollment in this U.S. study to further…
AJMC Introduces 14-part Video Series on Multiple Myeloma Treatment
This post was originally published on this site A new video series by the American Journal of Managed Care (AJMC) features experts discussing issues related to multiple myeloma treatment. Called “A Review of the Treatment for Multiple Myeloma,” the 14-part educational series is the AJMC’s latest panel discussion. “During this educational video series, our panel of experts, led…
Cerdulatinib Alone or with Rituxan Effective in Previously Treated Follicular Lymphoma, Data Show
This post was originally published on this site Treatment with the oral therapy cerdulatinib alone or in combination with Rituxan (rituximab) shows durable efficacy, including some complete responses, in patients with follicular lymphoma who failed prior medications, according to early results of a Phase 2a trial. The study, “Rapid and Durable Responses with the SYK/JAK…









